<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02262026</url>
  </required_header>
  <id_info>
    <org_study_id>1503015528</org_study_id>
    <nct_id>NCT02262026</nct_id>
  </id_info>
  <brief_title>The Tolerability and Effects of AZD0530 in Individuals With or Without a Family History of Alcoholism</brief_title>
  <official_title>A Phase One Study Investigating the Tolerability and Effects of AZD0530 on Functional Neuroimaging Responses in Individuals With or Without a Family History of Alcoholism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Functional neuroimaging of alcoholism vulnerability: glutamate, reward, impulsivity, and
      Pavlovian-to-instrumental transfer (PIT), part II Saracatinib
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the effect of oral AZ D0530 at various doses on neuroimaging parameters associated
      with various forms of impulsivity mediated through glutamate-dopamine interactions, as
      ascertained through functional magnetic resonance imaging. -- --NOTE-- AZD0530 dosage of 50mg
      was discontinued by manufacturer. Adjustments were made to account for the removal of the
      50mg dosage in all arms of the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">April 28, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 28, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BOLD activation during A1 phase</measure>
    <time_frame>4 Hours post medication administration</time_frame>
    <description>BOLD activation during the A1 phase of the MRI Monetary Incentive Delay task</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BOLD signal activation in the anterior cingulate cortex(ACC)</measure>
    <time_frame>4 Hours post medication administration</time_frame>
    <description>BOLD signal activation in the anterior cingulate cortex (ACC) observed during False Alarms of the GoNoGo Task</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Alcoholism</condition>
  <arm_group>
    <arm_group_label>FHP; 125mg AZD0530, then 50mg AZD0530, then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Family History positive for alcoholism will take place in blinded testing of 125 mg, then 50 mg, then placebo separated by 1 week for each test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FHP; 125mg AZD0530, then placebo, then 50mg AZD0530</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Family History positive for alcoholism will take place in blinded testing of 125 mg, then placebo, then 50mg separated by 1 week for each test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FHP; 50mg AZD0530, then 125mg AZD0530, then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Family History positive for alcoholism will take place in blinded testing of 50mg, then 125mg, then placebo separated by 1 week for each test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FHP; 50mg AZD0530, then placebo, then 125mg AZD0530</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Family History positive for alcoholism will take place in blinded testing of 50mg, then placebo, then 125mg separated by 1 week for each test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FHP; placebo, then 50mg AZD0530, then 125mg AZD0530</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Family History positive for alcoholism will take place in blinded testing of placebo, then 50 mg, then 125 mg separated by 1 week for each test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FHP; placebo, then 125mg AZD0530,then 50mg AZD0530</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Family History positive for alcoholism will take place in blinded testing of placebo, then 125 mg, then 50 mg separated by 1 week for each test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FHN; 125mg AZD0530, then 50mg AZD0530, then placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Family History negative for alcoholism will take place in blinded testing of 125 mg, then 50 mg, then placebo separated by 1 week for each test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FHN; 125mg AZD0530, then placebo, then 50mg AZD0530</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Family History negative for alcoholism will take place in blinded testing of 125 mg, then placebo, then 50mg separated by 1 week for each test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FHN; 50mg AZD0530, then 125mg AZD0530, then placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Family History negative for alcoholism will take place in blinded testing of 50mg, then 125mg, then placebo separated by 1 week for each test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FHN; 50mg AZD0530, then placebo, then 125mg AZD0530</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Family History negative for alcoholism will take place in blinded testing of 50mg, then placebo, then 125mg separated by 1 week for each test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FHN; placebo, then 50mg AZD0530, then 125mg AZD0530</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Family History negative for alcoholism will take place in blinded testing of placebo, then 50 mg, then 125 mg separated by 1 week for each test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FHN; placebo, then 125mg AZD0530, then 50mg AZD0530</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Family History negative for alcoholism will take place in blinded testing of placebo, then 125 mg, then 50 mg separated by 1 week for each test</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>125 mg AZD0530</intervention_name>
    <description>Randomized to receive 125 mg of AZD0530</description>
    <arm_group_label>FHP; 125mg AZD0530, then 50mg AZD0530, then placebo</arm_group_label>
    <arm_group_label>FHP; 125mg AZD0530, then placebo, then 50mg AZD0530</arm_group_label>
    <arm_group_label>FHP; 50mg AZD0530, then 125mg AZD0530, then placebo</arm_group_label>
    <arm_group_label>FHP; 50mg AZD0530, then placebo, then 125mg AZD0530</arm_group_label>
    <arm_group_label>FHP; placebo, then 50mg AZD0530, then 125mg AZD0530</arm_group_label>
    <arm_group_label>FHP; placebo, then 125mg AZD0530,then 50mg AZD0530</arm_group_label>
    <arm_group_label>FHN; 125mg AZD0530, then 50mg AZD0530, then placebo</arm_group_label>
    <arm_group_label>FHN; 125mg AZD0530, then placebo, then 50mg AZD0530</arm_group_label>
    <arm_group_label>FHN; 50mg AZD0530, then 125mg AZD0530, then placebo</arm_group_label>
    <arm_group_label>FHN; 50mg AZD0530, then placebo, then 125mg AZD0530</arm_group_label>
    <arm_group_label>FHN; placebo, then 50mg AZD0530, then 125mg AZD0530</arm_group_label>
    <arm_group_label>FHN; placebo, then 125mg AZD0530, then 50mg AZD0530</arm_group_label>
    <other_name>saracatinib</other_name>
    <other_name>AZD0530</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50 mg AZD0530</intervention_name>
    <description>Randomized to receive 50 mg of AZD0530</description>
    <arm_group_label>FHP; 125mg AZD0530, then 50mg AZD0530, then placebo</arm_group_label>
    <arm_group_label>FHP; 125mg AZD0530, then placebo, then 50mg AZD0530</arm_group_label>
    <arm_group_label>FHP; 50mg AZD0530, then 125mg AZD0530, then placebo</arm_group_label>
    <arm_group_label>FHP; 50mg AZD0530, then placebo, then 125mg AZD0530</arm_group_label>
    <arm_group_label>FHP; placebo, then 50mg AZD0530, then 125mg AZD0530</arm_group_label>
    <arm_group_label>FHP; placebo, then 125mg AZD0530,then 50mg AZD0530</arm_group_label>
    <arm_group_label>FHN; 125mg AZD0530, then 50mg AZD0530, then placebo</arm_group_label>
    <arm_group_label>FHN; 125mg AZD0530, then placebo, then 50mg AZD0530</arm_group_label>
    <arm_group_label>FHN; 50mg AZD0530, then 125mg AZD0530, then placebo</arm_group_label>
    <arm_group_label>FHN; 50mg AZD0530, then placebo, then 125mg AZD0530</arm_group_label>
    <arm_group_label>FHN; placebo, then 50mg AZD0530, then 125mg AZD0530</arm_group_label>
    <arm_group_label>FHN; placebo, then 125mg AZD0530, then 50mg AZD0530</arm_group_label>
    <other_name>saracatinib</other_name>
    <other_name>AZD0530</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>FHP; 125mg AZD0530, then 50mg AZD0530, then placebo</arm_group_label>
    <arm_group_label>FHP; 125mg AZD0530, then placebo, then 50mg AZD0530</arm_group_label>
    <arm_group_label>FHP; 50mg AZD0530, then 125mg AZD0530, then placebo</arm_group_label>
    <arm_group_label>FHP; 50mg AZD0530, then placebo, then 125mg AZD0530</arm_group_label>
    <arm_group_label>FHP; placebo, then 50mg AZD0530, then 125mg AZD0530</arm_group_label>
    <arm_group_label>FHP; placebo, then 125mg AZD0530,then 50mg AZD0530</arm_group_label>
    <arm_group_label>FHN; 125mg AZD0530, then 50mg AZD0530, then placebo</arm_group_label>
    <arm_group_label>FHN; 125mg AZD0530, then placebo, then 50mg AZD0530</arm_group_label>
    <arm_group_label>FHN; 50mg AZD0530, then 125mg AZD0530, then placebo</arm_group_label>
    <arm_group_label>FHN; 50mg AZD0530, then placebo, then 125mg AZD0530</arm_group_label>
    <arm_group_label>FHN; placebo, then 50mg AZD0530, then 125mg AZD0530</arm_group_label>
    <arm_group_label>FHN; placebo, then 125mg AZD0530, then 50mg AZD0530</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clear History of at least 1 parent having a history of alcoholism or no first or
             second degree relatives with alcoholism or substance abuse

        Exclusion Criteria:

          1. Exclusion criteria include: Current diagnosis of DSM-IV-TR Axis I disorder

          2. Report of psychotic disorder in a 1ยบ relative

          3. Auditory or visual impairment that interferes with test taking

          4. History of prenatal exposure to alcohol plus currently meeting criteria for features
             of fetal alcohol syndrome

          5. Not speaking English fluently or being a non-native English speaker, or being educated
             in a primary language other than English &gt;grade 1

          6. Mental retardation (Full Scale IQ&lt;70) using 2 WASI subtests for IQ estimate

          7. Traumatic brain injury with loss of consciousness &gt; 30 minutes, or concussion in last
             30 days

          8. Presence or history of any medical/neurologic illness that may affect brain physiology
             (e.g., epilepsy, Multiple Sclerosis), including focal brain lesion seen on structural
             MRI (all structural scans are read by a licensed radiologist)

          9. Current pregnancy (all females will be tested with urine screens on the day of MRI and
             prior to each phase of drug treatment)

         10. Positive urine screen for the presence of marijuana, cocaine, opiates or breath screen
             to detect the presence of alcohol, administered at each lab visit.

         11. Inability to comprehend the consent form appropriately

         12. Ferromagnetic metal devices, clips or fragments in body (orbital x-ray performed if
             needed).

         13. Current use (within 30 days of screening) of specific psychoactive medications (e.g.,
             typical neuroleptics, narcotic analgesics, antiparkinsonian medications, systemic
             corticosteroids, or medications with significant central anticholinergic activity,
             etc.). Current use of warfarin.

         14. Current use of the following medications (CYP3A4 substrates whose metabolism may be
             slowed by AZD0530): carbamazepine, colchicine, cyclosporine, disopyramide,
             fluticasone, quinidine, vinblastine, vincristine, nifedipine. Patients taking
             sildenafil, tadalafil, and vardenafil will be advised to stop taking these medications
             for the duration of the trial. Patients cannot take the following drugs which inhibit
             the CYP3A4 isoenzyme: cimetidine, cyclosporine, danazol, fluconazole, grapefruit
             juice, HIV protease inhibitors, itraconazole, ketoconazole, macrolides, miconazole,
             nefazodone, omeprazole, ritonavir, and verapamil, aromatase inhibitors, docetaxel

         15. Neutropenia defined as absolute neutrophils count of &lt;1,500/microliter.

         16. Thrombocytopenia defined as platelet count &lt;100x103/microliter.

         17. AST, ALT, total bilirubin &gt;1.5 times upper normal; serum creatinine, &gt;2 time upper
             normal limit, total bilirubin&gt;1.5 times ULN; Serum creatinine &gt;2.0 times ULN.

         18. History of interstitial lung disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Godfrey D Pearlson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Godfrey D Pearlson, MD</last_name>
    <phone>203-737-3416</phone>
    <email>Godfrey.Pearlson@hhchealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Godfrey Pearlson, MD</last_name>
      <phone>203-737-3416</phone>
      <email>godfrey.pearlson@hhchealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2014</study_first_submitted>
  <study_first_submitted_qc>October 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2014</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saracatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

